Institutional Registry of Rare Diseases

Study Purpose

The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD). Moreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational [Patient Registry]
Eligible Ages N/A and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Clinical and/or molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, or Cushing Syndrome.
  • - Must be followed at Hospital Italiano de Buenos Aires.

Exclusion Criteria:

  • - Refusal to participate in the study or in the informed consent process.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06573723
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Hospital Italiano de Buenos Aires
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Marcelo Serra, PhDSoledad Kleppe, MDMaria Lourdes Posadas Martinez, PhDLuis Mazzuoccolo, MDMaría Fabiana Russo Picasso, MDEduardo Jorge Premoli, MDMariano Martín Marcolongo, MDJavier Pollan, MDAdrian Gadano, MDPablo Lobos, MDHernan Garcia Rivello, MDMarcelo Risk, PhDMarcelo Rugiero, MDJulio Busaniche, MDRodolfo Pizarro, MD
Principal Investigator Affiliation HIBAHIBAHIBAHIBA - dermatologíaHIBA - endocrinologíaHIBA - oftalmologíaHIBA - gastroenterologíaHIBA - clínica médicaHIBA - investigaciónHIBA - cirugía pediátricaHIBA - patología clínicaIMTIBHIBA - neurologíaHIBA - clínica pediátricaHIBA - cardiología
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries Argentina
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, Cushing Syndrome
Additional Details

Rare Diseases (RD) pose a health challenge due to their complexity and low prevalence, generating a burden in terms of morbidity and mortality and costs. The fragmentation of data on these diseases makes it difficult to understand them comprehensively. Therefore, the creation of a macro institutional registry that brings together information on RD would facilitate research in this field. The registries are organized systems of systematic data collection of a large number of patients quickly and efficiently on a particular disease at a given time. The main difficulty of the registries is the guarantee of the quality of their data. The main objectives of the registry are: Understand risk factors and prognosis. Evaluate the diagnostic and therapeutic comparison with current standards. Advance knowledge of the disease to optimize the assessment, treatment and monitoring of patients. Analyze the effectiveness of new therapies. Studying differences between populations. Quickly estimate the morbidity, mortality and resource utilization associated with a disease entity. Examine the course of a disease Formulate novel hypotheses for further prospective studies.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Status

Recruiting

Address

Hospital Italiano de Buenos Aires

Buenos Aires, , C1199ABB

Site Contact

Ana Braslavsky, MD

[email protected]

+54 11 49590200 #4419

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Status

Recruiting

Address

Hospital Italiano de Buenos Aires

Buenos Aires, , C1199ABB

Site Contact

Ana Braslavsky, md

[email protected]

+54 11 49590200 #4419

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Status

Recruiting

Address

Hospital Italiano de Buenos Aires

Buenos Aires, , C1199

Site Contact

Maria L Posadas-Martinez, MD

[email protected]

54 11 4959 0200 #9353

Stay Informed & Connected